PPARG and breast cancer: Similarly, DMBA + ROSI-treated PPARγ-MG KOs showed a significant decrease in mammary tumour latency compared to similarly treated PPARγ-WT mice (with 25% of mice developing palpable mammary tumours at week 16 vs. 21.5, respectively; p < 0.05).